Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers

Trial Profile

Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs GLS 5300 (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Adverse reactions; First in man
  • Sponsors GeneOne Life Science
  • Most Recent Events

    • 23 Feb 2017 According to an Inovio Pharmaceuticals media release, positive Clinical Data was presented at the Coalition for Epidemic Preparedness Innovation (CEPI) 1st Scientific Meeting.
    • 23 Feb 2017 Interim results published in the Inovio Pharmaceuticals Media Release.
    • 06 Dec 2016 According to an Inovio Pharmaceuticals media release, interim data from this study is expected in early 2017 and publish the full data set in peer reviewed journals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top